The round is one of Europe’s largest-ever biotech VC deals, signalling investor appetite for the booming weight loss market.

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

To the Filipino doctor's utter dissapointment, he did not receive any financial compensation for his milestone discovery.

Eli Lilly & Company to establish new global capability centre in Hyderabad, recruiting over 1,000 professionals for advanced ...

A bill to lower the price of insulin drugs and supplies for more North Dakotans attracted passionate discussion at a Thursday ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 494.50% and ...

We recently published a list of 10 Best Blue Chip Stocks to Buy for 2025. In this article, we are going to take a look at ...

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.

New research from University of Iowa dispels the belief that pharmaceutical mergers lead to higher drug prices, showing a decrease in prices for generic drugs.

Zepbound is not covered by Medicare or many other insurance plans as a treatment for weight loss. The injectable treatment ...